Deutsche Bank Securities Reiterates BUY Rating on Anthera Pharmaceuticals (NASDAQ: ANTH) June 29, 2012
New York, June 29 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their BUY rating on the shares of Anthera Pharmaceuticals, Inc (NASDAQ: ANTH). The 12-month target price is set to $4.
In a research note published on June 28, the analysts mention that with Benlysta, initial take on PEARL-SC data-B-mod treatment effect is at best in line. Furthermore, as compared to that of placebo in lupus (PEARL-SC study), ph 2b data of B-mod was released by Anthera Pharmaceuticals.
At week number 20, with B-mod 200mg weekly, SRI 5 treatment difference was 13 percent in ITT population that at week 24, abated to 8.2 percent, which is simply the final stage of the process. In addition to this, at week number 52 and 76, difference of treatment for Benlysta laid in the range of 12.2 percent to 15.5 percent.
Nevertheless, for B-mod, therapy of background was locked at half the time, even though, for Benlysta at week number 24, anticipating treatment difference seems to be in the same ballpark as that of B-mod, the analysts add further.
News 
Market Data 
Discover 
